Logo path
/content/dam/pmequitypartner/portfolio-products/company-logos/Soft Hale V3.png
Novel inhalation technology

Softhale is developing pharmaceutical inhalation products for major respiratory markets in the U.S., Europe, and Asia. These products are based upon a differentiated inhalation delivery technology called SOFTHALER®. This device is a next-generation Soft Mist Inhaler (SMI), which offers a platform technology for delivering various drugs to the lungs. As well as generic products, innovative products are also targeted.

PM Equity Partner has exited its investment in Softhale.

Website url
Top Image
/content/dam/pmequitypartner/portfolio-products/Softhale 1.PNG
Left Image
/content/dam/pmequitypartner/portfolio-products/Softhale 2.PNG
Right Image
/content/dam/pmequitypartner/portfolio-products/Softhale 3.PNG